Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sabiporide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabiporide SCHEMBL4901732 | 0.99 | SLC9A1 (0.68) | SLC9A1CYP3A4CYP2C19HPGDSCA12 | |
| Sabiporide SCHEMBL29385812 | 0.99 | SLC9A1 (0.70) | SLC9A1CYP3A4CYP2C19HPGDSCA12 | |
| Sabiporide SCHEMBL1286662 | 0.99 | SLC9A1 (0.70) | SLC9A1CYP3A4CYP2C19HPGDSCA12 | |
| Sabiporide SCHEMBL5950959 | 0.95 | SLC9A1 (0.65) | SLC9A1CYP3A4CYP2C19HPGDSCA12 | |
| Hydrochloric Acid SCHEMBL6137232 | 0.86 | NPY2R (0.55) | SLC9A1CYP3A4CYP2C19NPY2R | |
| SCHEMBL6137414 | 0.83 | SLC9A1 (0.48) | SLC9A1CYP3A4CYP2C19NPY2R | |
| Hydrochloric Acid SCHEMBL6137329 | 0.83 | NPY2R (0.51) | SLC9A1CYP3A4CYP2C19NPY2R | |
| Sabiporide SCHEMBL1286649 | 0.83 | SLC9A1 (0.98) | SLC9A1CYP3A4CYP2C19 | |
| SCHEMBL1763885 | 0.82 | SLC9A1 (0.71) | SLC9A1CYP3A4CYP2C19 | |
| Sabiporide SCHEMBL4901735 | 0.82 | SLC9A1 (0.96) | SLC9A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080241077-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-10-02 | — | — | US | claimed |
| US-20080025919-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-01-31 | — | — | US | claimed |
| US-20070135446-A1 | Benzoylguanidlne salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-14 | — | — | US | claimed |
| US-20060217396-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-28 | — | — | US | claimed |
| US-20050043320-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-24 | — | — | US | claimed |
| US-20040122019-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | claimed |
| US-6730678-B2 | 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUOROMETHYLBENZ OYL GUANIDINE HYDROCHLORIDE AS SODIUM CHANNEL MODULATORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-04 | — | — | US | claimed |
| CN-1491213-A | Novel benzoylguanidine salt | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-04-21 | — | — | CN | claimed |
| US-20020137753-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-26 | — | — | US | claimed |
| EP-1362030-B1 | NOVEL BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-04-11 | — | — | EP | disclosed |
| JP-2009235097-A | NEW BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG | 2009-10-15 | — | — | JP | disclosed |
| US-20080241077-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-10-02 | — | — | US | disclosed |
| US-20080241077-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-10-02 | — | — | US | disclosed |
| US-20080025919-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | EICKMEIER CHRISTIAN | 2008-01-31 | — | — | US | disclosed |
| US-20030069207-A1 | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-10 | — | — | US | disclosed |
| WO-2003022281-A1 | IMPROVEMENT OF THE LOCAL COMPATIBILITY DURING INTRAVENOUS ADMINISTRATION OF 4-(4-(2-PYRROLYLCARBONYL)-1-PIPERAZINYL)-3-TRIFLUORMETHYL-BENZOYLGUANIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-20 | — | — | WO | disclosed |
| US-20020137753-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-26 | — | — | US | disclosed |
| US-20020137753-A1 | Benzoylguanidine salt and hydrates thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-26 | — | — | US | disclosed |
| WO-2002064563-A1 | NOVEL BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064563-A1 | NOVEL BENZOYLGUANIDINE SALT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080025919-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | SLC9A1, SLC9A2, SLC9A3 | CA2 244/4885SLC9A1 1/4885CYP3A4 1789/4885 |
| US-20070135446-A1 | Benzoylguanidlne salt and hydrates thereof | SLC9A1, SLC9A2, SLC5A1 | CA2 179/4885SLC9A1 1/4885CYP3A4 2882/4885 |
| US-20030069207-A1 | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | GIPR, SLC11A2, SLC10A2 | CA2 2494/4885SLC9A1 654/4885CYP3A4 127/4885 |
| US-20080241077-A1 | BENZOYLGUANIDINE SALT AND HYDRATES THEREOF | SLC9A1, SLC9A2, SLC9A3 | CA2 244/4885SLC9A1 1/4885CYP3A4 1789/4885 |
| US-20050043320-A1 | Benzoylguanidine salt and hydrates thereof | SLC9A1, SLC9A2, SLC9A3 | CA2 244/4885SLC9A1 1/4885CYP3A4 1789/4885 |
| US-20020137753-A1 | Benzoylguanidine salt and hydrates thereof | SLC9A1, SLC9A3, SLC9A2 | CA2 320/4885SLC9A1 1/4885CYP3A4 2281/4885 |
| US-20060217396-A1 | Benzoylguanidine salt and hydrates thereof | SLC9A1, SLC9A2, SLC9A3 | CA2 244/4885SLC9A1 1/4885CYP3A4 1789/4885 |
| US-20040122019-A1 | Benzoylguanidine salt and hydrates thereof | SLC9A1, SLC9A3, SLC9A2 | CA2 320/4885SLC9A1 1/4885CYP3A4 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.